Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder

@article{Frampton2014PregabalinAR,
  title={Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder},
  author={James E. Frampton},
  journal={CNS Drugs},
  year={2014},
  volume={28},
  pages={835-854}
}
Pregabalin (Lyrica®), a well established anxiolytic agent, has been approved in the EU for the treatment of generalized anxiety disorder (GAD) in adults. It has a distinct mechanism of action relative to other anti-anxiety agents (α2δ binding at presynaptic voltage dependent calcium channels leading to inhibition of excitatory neurotransmission), a rapid onset of effect (typically ≤1 week) and broad spectrum activity against both the psychic and somatic symptoms of GAD. In long-term studies… 

Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder

Pregabalin is an alternative compound to SSRIs and SNRIs for the first-line treatment of generalized anxiety disorder (GAD) and its favorable pharmacokinetic properties are all favorable for the treatment of GAD patients, including those with comorbid depressive symptoms or medical conditions.

Pregabalin in the Management of Painful Diabetic Neuropathy: A Narrative Review

The role of pregabalin in the management of pDPN as well as its potential adverse effects, such as somnolence and dizziness, which can lead to withdrawal in ~ 30% of long-term use are evaluated.

Gabapentin and Pregabalin for the Treatment of Anxiety Disorders

This review will focus on the comparative properties of gabapentin and pregabalin, specifically the available evidence on their use in the treatment of primary anxiety disorders — GAD, social anxiety disorder, panic disorder, and obsessivecompulsive disorder.

Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study.

This study does not support the usefulness of adding pregabalin in patients with GAD and UMD and with an early nonresponse to escitalopram.

Safety and Tolerability of Anxiolytics/Sedative-Hypnotics

Emerging evidence indicates that pregabalin, a pharmacological agent approved for the treatment of generalized anxiety disorder, also has the potential to lead to abuse and dependence, and is still valuable in the management of anxiety disorders and transient insomnia.

Pregabalin-induced sexual disinhibition

A greater clinical recognition of this association between pregabalin and sexual disinhibition, would allow clinicians to intervene at an earlier stage of this adverse effect and potentially as in this case, management may only require dose reduction rather than treatment discontinuation.

Pregabalin Addiction in a Case with Synthetic Cannabinoid Use

The anxiolytic effects of pregabalin are similar to the benzodiazepines and occur rapidly after administration, however, the Food and Drug Administration in the USA and European Medicines Agency (EMA) have included the drug in the “Schedule V Controlled Substances”.

Use and safety of antiepileptic drugs in psychiatric inpatients—data from the AMSP study

The psychiatric utilization patterns and risks of antiepileptic drugs (AEDs) were assessed by using data from the drug safety programme Arzneimittelsicherheit in der Psychiatrie over the time period 1993–2013, with main indications for AED use being acute mania, schizoaffective disorder, and schizophrenic and organic psychoses.

Letter: a randomised clinical trial comparing the effects of pregabalin with those of placebo on functional dyspepsia. Authors’ reply

A subgroup analysis in patients with suspected anxiety disorder, and those without (HADS anxiety score ≤8), suggests that the efficacy of pregabalin in functional dyspepsia might not only be attributed to its antianxiety properties.

Gabapentin and Pregabalin: Do the Benefits Outweigh the Harms?

Prescribers should be aware of the very limited clinical evidence for use of gabapentin and pregabalin outside their licensed indications, as well as their capacity to do harm.
...

References

SHOWING 1-10 OF 89 REFERENCES

Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention

Randomized, controlled trials confirm that pregabalin is superior to placebo and comparable with lorazepam, alprazolam and venlafaxine for the treatment of patients with moderate-to-severe GAD.

Pregabalin for the treatment of generalized anxiety disorder: an update

The findings of randomized controlled trials and meta-analyses together indicate that pregabalin is efficacious in both acute treatment and relapse prevention in GAD, with some evidence of an early onset of effect, and broad efficacy in reducing the severity of psychological and physical symptoms of anxiety.

Pharmacotherapy Update: Pregabalin in the Treatment of Generalized Anxiety Disorder

Data is summarized showing that pregabalin has a significantly different safety profile from the benzodiazepines, SSRI/ SNRI anxiolytics, and SSRIs/SNRIs (eg, less gastrointestinal side effects and sexual dysfunction).

Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin

Evidence from available randomized placebo-controlled as well as head-to-head clinical trials with other drugs regarding its efficacy and safety in the GAD treatment is evaluated.

Pregabalin: in the treatment of generalised anxiety disorder.

Oral pregabalin, typically at dosages of 300-600 mg/day, was superior to placebo and similar to lorazepam, alprazolam and venlafaxine in improving anxiety and depressive symptoms in patients with moderate-to-severe generalised anxiety disorder (GAD).

Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder

Pregabalin, in doses of 150–600 mg/day, was a safe and effective treatment of generalised anxiety disorder in patients 65 years and older and had an early onset and significantly improved both psychic and somatic symptoms of anxiety.

Pregabalin: dose-response relationship in generalized anxiety disorder.

  • M. Boschen
  • Psychology, Medicine
    Pharmacopsychiatry
  • 2012
Examination of the dose-response relationship for treatment of GAD with pregabalin found peak reduction in anxiety symptoms was observed to occur at a dose of approximately 450 mg/day, with a small reduction in treatment effect beyond this dose.

Effects of pregabalin on sleep in generalized anxiety disorder.

This review summarizes the results of clinical trials and pooled analyses that provide data on pregabalin's effect on sleep disturbance in patients diagnosed with GAD and suggests that improvement in sleep has been found to be associated with a reduction in daytime sleepiness.

A Meta-Analysis of the Efficacy of Pregabalin in the Treatment of Generalized Anxiety Disorder

  • M. Boschen
  • Psychology
    Canadian journal of psychiatry. Revue canadienne de psychiatrie
  • 2011
Pregabalin is an efficacious therapy for GAD, although effect sizes are smaller than those from earlier studies.
...